Bio-Rad Laboratories Inc. Class B

600.87+21.49+3.71%Vol 2001Y Perf 50.04%
Apr 12th, 2021 18:40 DELAYED
BID615.15 ASK616.95
Open600.87 Previous Close579.38
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     71.42
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     84.79
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap17.93B 
Earnings Rating
Buy
Price Range Ratio 52W %
74.75 
Earnings Date
5th May 2021

Today's Price Range

600.87600.87

52W Range

400.47668.56

5 Year PE Ratio Range

5.60275.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.71%
1 Month
0.03%
3 Months
-0.79%
6 Months
13.37%
1 Year
50.04%
3 Years
140.49%
5 Years
340.94%
10 Years
-

TickerPriceChg.Chg.%
BIO.B600.8721.49003.71
AAPL134.423.18002.42
GOOG2 273.4818.69000.83
MSFT258.452.54000.99
XOM55.700.20000.36
WFC39.79-0.9800-2.40
JNJ159.54-2.1000-1.30
FB311.19-0.3500-0.11
GE13.49-0.1000-0.74
JPM154.58-1.3700-0.88
Financial StrengthValueIndustryS&P 500US Markets
2.20
3.40
0.02
0.02
225.50
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
56.50
193.60
199.10
52.70
84.36
RevenueValueIndustryS&P 500US Markets
1.97B
389.18
4.41
4.54
Earnings HistoryEstimateReportedSurprise %
Q03 2020-3.00-
Q02 2020-1.61-
Q01 2020-1.91-
Q04 2019-2.32-
Q03 2019-1.61-
Q02 2019-1.57-
Q01 2019-1.65-
Q04 2018-2.13-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume200
Shares Outstanding29.84M
Trades Count33
Dollar Volume30.12K
Avg. Volume174
Avg. Weekly Volume120
Avg. Monthly Volume190
Avg. Quarterly Volume182

Bio-Rad Laboratories Inc. Class B (NYSE: BIO.B) stock closed at 600.87 per share at the end of the most recent trading day (a 3.71% change compared to the prior day closing price) with a volume of 218.0000 shares and market capitalization of 17.93B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class B CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class B stock is 50.04%, while year-to-date (YTD) performance is 4.65%. BIO.B stock has a five-year performance of 340.94%. Its 52-week range is between 400.47 and 668.56, which gives BIO.B stock a 52-week price range ratio of 74.75%

Bio-Rad Laboratories Inc. Class B currently has a PE ratio of 4.60, a price-to-book (PB) ratio of 1.75, a price-to-sale (PS) ratio of 1.54, a price to cashflow ratio of 30.40, a PEG ratio of 2.32, a ROA of 35.09%, a ROC of 46.36% and a ROE of 47.15%. The company’s profit margin is 84.36%, its EBITDA margin is 199.10%, and its revenue ttm is $1.97 Billion , which makes it $389.18 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class B, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bio-Rad Laboratories Inc. Class B’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class B is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class B stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class B has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class B has a Buy technical analysis rating based on Technical Indicators (ADX : 83.19, ATR14 : 485.67, CCI20 : 80.35, Chaikin Money Flow : -0.68, MACD : -2.66, Money Flow Index : 51.37, ROC : 3.71, RSI : 56.16, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 99.97, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class B in the last 12-months were: Andrew J. Last (Option Excercise at a value of $0), Annette Tumolo (Option Excercise at a value of $191 184), Annette Tumolo (Sold 1 200 shares of value $768 865 ), Dara Wright (Option Excercise at a value of $0), Giovanni Magni (Option Excercise at a value of $2 579 316), Giovanni Magni (Sold 15 229 shares of value $7 914 650 ), Ilan Daskal (Option Excercise at a value of $0), Michael Crowley (Option Excercise at a value of $0), Michael Crowley (Sold 1 874 shares of value $945 271 ), Norman Schwartz (Option Excercise at a value of $6 258 180), Ronald W. Hutton (Option Excercise at a value of $0), Ronald W. Hutton (Sold 443 shares of value $202 606 ), Timothy S. Ernst (Option Excercise at a value of $63 728), Timothy S. Ernst (Sold 923 shares of value $591 501 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Bio-Rad Laboratories Inc. Class B

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

42%58%

Bearish Bullish

61%39%

Bearish Bullish

67%33%

News

Stocktwits